Notably, such a process may take place both in the spleen, which, together with the liver, represent the major storage organ upon ferric isomaltoside treatment, and in the tumor milieu displaying improved iron availability as demonstrated by reduced CD71 levels on the bona-fide neoplastic epithelium. Here, TFRC is linked to neoplasm.